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In the present report we provide evidence that SRP-35, a protein we identified in 
rabbit skeletal muscle sarcoplasmic reticulum, is an all-trans retinol dehydrogenase. 
Analysis of the primary structure and tryptic digestion revealed that its NH2-terminal 
encompasses a short hydrophobic sequence bound to the sarcoplasmic reticulum 
membrane, while its COOH-terminal catalytic domain faces the myoplasm. SRP-35 is 
also expressed in liver and adipocytes where it appears in the post-microsomal 
supernatant, however in skeletal muscle SRP-35 is enriched in the longitudinal 
sarcoplasmic reticulum. Sequence comparison predicts that SRP-35 is a short-chain 
dehydrogenase/reductase belonging to the DHRS 7C subfamily. Retinol is the substrate 
of SRP-35 since its transient over-expression leads to an increased production of all-
trans retinaldehyde. Transfection of C2C12 myotubes with a fusion protein encoding 
SRP-35-EYFP causes a decrease of the maximal Ca2+ released via ryanodine receptor 
activation induced by KCl or 4-chloro-m-chresol. The latter result could be mimicked 
by the addition of retinoic acid to the C2C12 cell tissue culture medium, a treatment 
which caused a significant reduction of RyR1 expression. We propose that in skeletal 
muscle SRP-35 is involved in the generation of all-trans retinaldehyde and may play an 
important role in the generation of intracellular signals linking Ca2+ release (i.e. muscle 
activity) to metabolism. 
  
     Introduction 
The skeletal muscle sarcoplasmic reticulum (SR) is an intracellular membrane compartment 
highly specialized in calcium homeostasis. Structurally it can be subdivided into two 
membrane portions: the terminal cisternae facing the transverse tubules, and the longitudinal 
sarcoplasmic reticulum (LSR) that connects two terminal cisternae [1]. Depolarization of the 
plasma membrane causes the Ca2+ stored in the SR to be released, leading to muscle 
contraction by a process known as excitation-contraction coupling [2,3]; Ca2+ is then pumped 
back into the SR via sarco(endo)plasmc reticulum Ca2+ ATPases (SERCAs) which are 
located on the terminal cisternae and LSR, leading to muscle relaxation [4-6]. These highly 
  
 
2 
coordinated events occur within milliseconds thanks to the spatial organization of the 
membrane compartments carrying the different proteins involved in sensing plasma 
membrane depolarization, Ca2+ release and Ca2+ uptake [7]. Indeed, excitation-contraction 
coupling occurs at the triad a structure made up of the transverse tubules (which are 
invaginations of the plasma membrane), carrying the voltage sensing dyhydropyridine 
receptor (DHPR), and two terminal cisternae carrying the ryanodine receptor (RyR) Ca2+ 
release channel [8,9]. Although these two Ca2+ channels are the basic unit underlying 
excitation-contraction coupling, they nevertheless function in coordination with a number of 
accessory proteins and enzymes involved in maintaining the architecture and optimal 
function of the calcium release unit. Because of their potential roles in regulating excitation-
contraction coupling and since they may be targets of mutations causing neuromuscular 
disorders, several laboratories have focused their research on identifying novel proteins 
present on these specialized intracellular membrane compartments and a number of minor 
components including mitsugumins, junctophilins, junctate, JP-45 and SRP27 have recently 
been characterized [for recent reviews see 10, 11]. 
 In the present study, using a proteomic approach we identified a 35 kDa protein in 
skeletal muscle SR which we called SRP-35, for sarcoplasmic reticulum protein of 35 kDa. 
Sequence motif comparison indicates that this protein belongs to the DHRS7C short chain 
dehydrogenase (SDR) subfamily [12] and is likely to catalyse the conversion of all-trans 
retinol to retinaldehyde by reducing the cofactor NAD+ to NADH [13]. SDRs are 
ubiquitously expressed and constitute a large protein family involved in the reduction of a 
variety of substrates, among which, retinol, the precursor of retinoic acid [14]. In vertebrates 
the effectors of RA signalling belong to the nuclear receptor family that are divided into two 
subgroups: the nuclear retinoic-acid receptors, (RARα/ß/γ) and the retinoid-X receptors 
(RXRα/ß/γ) [15-18]. Upon RA binding to RAR, the receptors undergo hetero-dimerization 
with RXRs and translocate into the nucleus, where they bind to target DNA sequences known 
as retinoic-acid response elements promoting the transcription of several genes, including 
some involved in growth, development, differentiation, cytokine production and metabolism 
[14,19]. Interestingly, treatment of mice with all-trans RA reduces body weight, adipose 
tissue content and promotes skeletal muscle fatty acid oxidation [20]. Thus SRP-35 may be 
part of a signalling pathway linking muscle activity and metabolism; indeed this polypeptide 
is enriched in tissues involved in fatty acid metabolism, notably liver, adipose tissue, kidney 
and skeletal muscle. Interestingly in the latter tissue it is enriched in the longitudinal 
sarcoplasmic reticulum where a number of glycolytic enzymes such as pyruvate kinase, 
aldolase, enolase and glyceraldehyde 3-phosphate dehydrogenase have also been found to 
compartmentalize [21]. Since SRP-35 oxidizes all-trans retinol (ROL) to all-trans 
retinaldehyde (RAL) at a site directly involved in Ca2+ homeostasis, we hypothesize that 
SRP-35 might have a dual function: (i) reduce NAD+ linked to lactic acid generation. The 
NADH would in turn down-regulate Ca2+ release by affecting the redox equilibrium adjacent 
to RyR1 (the skeletal muscle isoform of the RyR); (ii) regulate skeletal muscle gene 
transcription via the retinoic acid receptor pathway.  
 
Experimental procedures 
Materials 
Anti-calregulin and anti-calnexin antibodies, peroxidase-conjugated protein A, 
Trypsin-EDTA, DMEM, MEM plus Earls salts, L-Glutamine, Pennicillin/Streptomycin, 
horse serum, foetal bovine serum, Deoxyribonuclease I, Alexa Fluor 488 chicken anti-rabbit 
IgG and Alexa Fluor 568 donkey anti-mouse IgG were from Invitrogen. All-trans retinol and 
all-trans retinaldehyde, protein-A Sepharose, ESCORT IV, peroxidase conjugated protein G, 
peroxidase conjugated anti-mouse IgG and rabbit anti-DHRS7C Abs were from Sigma-
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Aldrich. Mouse mAb anti-RyR1 (MA3-925) and anti-SERCA (MA3-910) were from Thermo 
Scientific. The pGEX-5X-3 plasmid and HiTrap Blue Sepharose were from GE Healthcare. 
The UNI-ZAP XR cDNA library, pEYFP-C1, pEGFP-C1 plasmids were from Clontech. Goat 
anti-DHPRα1.1 was from Santa Cruz. Anti-albumin antibodies were from Bethyl laboratories 
(Montgomery, TX., U.S.A). Oxy-Blot protein oxidation detection kit was from Millipore. 
Nitrocellulose membrane was from Schleicher & Schuell BioScience GmbH. Protein 
Molecular Weight markers and the Protein Assay kit were from Biorad. NAD+, NADH, 
NADP+, FuGene 6, anti-proteases, Taq polymerase were from Roche Diagnostics. The High 
Capacity cDNA Reverse transcription kit and fast SYBR green master mix were from 
Applied Biosystems (Forster City, CA, U.S.A.) Fura-2 acetoxymethylester was from 
Calbiochem. Tri-Reagent (Molecular Research Center Inc.). PCR primers were from 
Microsynth A.G. (Balgach, Switzerland). Paraffin-embedded mouse skeletal muscle sections 
were from Ciochain Institute Inc. (BioCat, Heidelberg, Germany). All other chemicals were 
reagent of highest available grade. Mice were bred in house and rabbits (NZW) were 
purchased from Charles Rivers Laboratories. All procedures were performed in accordance 
with the stipulations of the Helsinki Declarations for care and use of laboratory animals. 
Methods 
Protein sequencing: proteins present in the terminal cisternae  and junctional face membrane 
fractions were separated on a 10%  SDS PAG prepared under ultraclean conditions and 
allowed to polymerise at room temperature for 72 hours; the gel was stained with Coomassie 
Brilliant Blue R250 (0.1% CBB R250 in 50% MetOH, 0.1% Ac Acid) and destained 
overnight at 4°C in 1% acetic acid, 50% Methanol; the 35 kDa band was cut out with a clean 
scalpel blade and the SDS and CBB were removed by slicing the gel finely in 40% n-
propanol, washing and vortexing the sample and changing the solution many times. After the 
last n-propanol wash, the gel was resuspended in a solution containing 0.2 M NH4HCO3/40% 
acetonitrile and washed with this solution 5 times. After the final wash, excess liquid was 
removed and the gel fragments dried in a speedvac. The sample was then rehydrated in 0.1 M 
NH4CO3/trypsin (sequencing grade, 25 ng/µl) and incubated at 37°C overnight. The 
supernatant was then collected and transferred to a clean tube; the pellet was treated with a 
solution made up by 80% acetonitrile/0.1% trifluoroacetic acid to extract remaining peptides. 
The two supernantants were combined and dried in a speedvac and then subjected to Mass 
Spec analysis using a Q-TOF (Micromass, Manchester, UK) mass spectrometer [22].  
 
SRP-35 cDNA cloning- Total RNA was isolated from mouse skeletal muscles using Tri-
Reagent following the instructions provided by the manufacturer. Total RNA was converted 
to cDNA as previously described [23] and primers were designed based on the peptide 
sequence obtained from trypsin digestion of rabbit SRP-35. These primers (5’-
GGAGAGCCTCTACGCTGCCT-3’and 5’-ACGCCAACTACTTTGGACCCA -3’ for 
forward and reverse reactions, respectively) were used to amplify a sequence from mouse 
skeletal muscle cDNA; a band of approximately 220 bp was obtained using the following 
amplification conditions: 1 cycle 95°C 5 min followed by 35 cycles annealing (55°C, 30 sec), 
extension (72°C, 45 sec), denaturation (95°C, 45 sec), followed by a 5 min extension cycle at 
72°C. The PCR-amplified cDNA was then used as a probe to screen a mouse skeletal muscle 
UNI-ZAP XR cDNA library as previously described [23]. A clone of 960 bp, containing the 
entire ORF was pulled out and sequenced (Microsynth AG, Balgach, Switzerland). The 
coding sequence of SRP-35 was subcloned into the pGEX-5X-3 bacterial expression plasmid 
and into pEGFPC1 and pEYFPC1 for expression in mammalian cells. 
Cell culture and transfection- C2C12 cells were cultured in growth medium (DMEM+ 
glutamax+ high glucose (4.5g/l), 20% foetal calf serum, 200mM L-glutamine, penicillin/ 
streptomycin) and maintained below confluence. For differentiation into myotubes, cells were 
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allowed to reach 70% confluence then the medium was switched to differentiation medium 
(DMEM+ Glutamax+ high glucose, 5% horse serum, 200mM L-glutamine, penicillin/ 
streptomycin), until cells had visibly fused into myotubes (about 5 days). Transfection of 
C2C12 cells was carried out using FuGene 6 at a ratio of 1.5 µl FuGene per µg plasmid DNA 
per ml culture media. Cells were transfected on day 1 and 3 following switch to 
differentiation medium and harvested on day 4 post differentiation. In some experiments 
C2C12 were incubated for 4 days with retinoic acid (5 µM) during differentiation. 
 HEK 293 cells were cultured and transfected with the pEGFPC1 and pEGFPC1-SRP-
35-plasmids using ESCORT IV as previously described [24].  
Subcellular fractionation, trypsin digestion and fluorescence analysis- Total microsomes 
from different mouse tissues (heart, lung, brain, kidney, skeletal muscle, liver, spleen, 
stomach, intestine), total homogenates prepared form mouse tissues and from isolated fast 
(EDL) and slow (soleus) fibres, and skeletal muscle SR subfractions enriched in plasma 
membrane, terminal cisternae and longitudinal SR were prepared as described [1,23,24]. In 
order to determine if SRP-35 is an integral membrane protein, mouse skeletal muscle SR 
vesicles were treated with Na2CO3/KCl, as previously described [25]. Fifteen micrograms of 
mouse skeletal muscle SR were digested with increasing concentrations of trypsin, for 2 
minutes at room temperature. The reaction was blocked by the addition of trypsin inhibitor; 
samples were then loaded onto a 12.5% SDS PAG, blotted onto nitrocellulose and probed 
with the indicated antibodies. Localization of GFP-tagged recombinant proteins in transfected 
C2C12 cells was performed 48 hours after transfection. Briefly, myotubes were fixed with 
3.7% paraformaldehyde (in PBS), mounted in glycerol medium and observed under 
fluorescent light (excitation 480 nm, emission 510 nm) with an inverted fluorescent 
microscope (Axiovert S100 TV/Carl Zeiss GmbH) equipped with a 20x water-immersion 
FLUAR objective (0.75 numerical aperture) attached to a Cascade 128+ CCD camera 
(Photometrics).  
Polyclonal antibody production, Western blotting and confocal microscopy- Polyclonal 
antibodies raised against the recombinant GST-SRP-35 fusion protein were obtained by 
immunizing rabbits and the IgG fraction was purified as previously described [25]. 
Alternatively, commercial rabbit anti-DHRS7C were tested on blotted proteins and indirect 
immuno-enzymatic staining was carried out as previously described [25]. Confocal 
microscopy was performed on paraffin embedded mouse skeletal muscle tissue sections; 
briefly, sections were re-hydrated by incubating sequentially in Xylene (2 times, 2 min), 
100% ethanol (2 times, 30 sec), 95% and 80% ethanol (1 time, 30 sec) followed by H20 (3 
times, 3 min) and equilibration in PBS; membranes were permeabilized for 30 min at room 
temperature with a solution containing 0.5% Triton X-100, 2% horse serum and 1% BSA; 
slides were then incubated with the primary antibody (rabbit anti-DHRS7C and mouse anti-
SERCA mAb diluted in 0.01% Triton X-100, 1% BSA, 2% horse serum in PBS overnight at 
4°C, followed by 4 washes 15 min each with PBS and incubation for 40 minutes at room 
temperature with Alexa Fluor-488 chicken anti-rabbit IgG and Alexa Fluor-568 donkey anti-
mouse IgG diluted in  0.01% Triton X-100, 1% BSA, 2% horse serum in PBS. Slides were 
mounted and fluorescence observed by confocal microscopy using a Leica DM1400 confocal 
microscope equipped with a 100x HCX APO TIRF objective (1.47 NA).  
Affinity Chromatography- In order to determine whether SRP-35 is a dinucleotide binding 
protein, we used the affinity column HiTrap Blue Sepharose; the ligand Cibacron Blue F3G-
A shows structural similarities to NAD(H) enabling proteins strongly binding to this cofactor 
to attach to the resin [26]. Total SR vesicles (1 mg/ml) were solubilised for 30 min at 4° C in 
a solution containing 10 mM Tris-HCl pH 8.0, 1% DDM, 1 M NaCl.  The solubilised SR 
membrane proteins were diluted 10 times with a solution containing Tris-HCl pH 8.0, 1 M 
NaCl and then incubated with Cibacron Blue F3G-A Sepharose previously equilibrated with 
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10 mM Tris-HCl pH 8.0, 0.1 % DDM, 1M NaCl. The resin was washed with 10 bed volumes 
of buffer containing 10 mM Tris-HCl pH 8.0, 0.1 % DDM, 1M NaCl and proteins were 
eluted by adding 1 mM NADH. In order to verify if some SRP-35 was still bound to the 
resin, 100 µl of laemmli loading buffer were added to the Cibacron Blue F3G-A Sepharose, 
after 5 min of incubation, samples were centrifuged and 30 µl of supernatant were loaded on 
the gel.   
Ca2+ release and KCl-dose response curves- glass cover slip grown, transfected (with 
pEYFPC1 or pEYFPC1-SRP-35) and differentiated C2C12 cells were loaded with the 
ratiometric Ca2+ indicator fura-2-AM (5µM) in Krebs-Ringer for 30 minutes at 37°C. YFP-
positive cells were first identified using a 40x Plan-Neofluar objective (NA 1.3) and filter set 
N°44 (Carl Zeiss MicroImaging, Inc.; BP 475/40, FT 500, BP 530/50) as previously 
described [24]. Transfected cells were then analysed for their response to pharmacological 
activation with KCl or 4-chloro-m-cresol, or for the status of the intracellular Ca2+ stores by 
treating the cells with 5 µM ionomycin plus 1 µM thapsigargin in Krebs Ringer containing no 
added Ca2+ and 0.5 mM EGTA, by monitoring the changes in fura-2 fluorescence [27]. 
Images were acquired with a Cascade 128+ CCD camera and analysed using the Metamorph 
imaging software 7.7.0.0. Generation of dose response curves and statistical analysis were 
performed using Windows GraphPad Prism v.4.00 (GraphPad Software Inc.). For some 
experiments myotubes were treated with retinoic acid (5 µM) for 4 days, loaded with fura-2 
and analysed for their calcium response to KCl and 4-chloro-m-cresol as indicated above. 
Retinol/retinal enzymatic assays- HEK293 cells were transfected with pEYFPC1 or 
pEYFPC1-SRP-35 and 24 hours post transfection either all-trans retinol (10 µM) was added 
to the cell medium for 6 h, or all-trans retinaldehyde (5 µM) was added to the cell medium 
for 3 h. After incubation, the cells were washed twice with PBS and the medium replaced 
with 1 ml 100% methanol and 1 ml 2 M hydroxylamine pH 6.7. Cells were subsequently 
scraped off from the tissue culture flask, homogenized in a glass potter and after a 10 min 
incubation at room temperature, the homogenate was stored at –80°C until used. 
For retinol quantification, all solutions were made diluting a stock solution of all-trans 
retinol or all-trans retinaldehyde prepared in 100% ethanol, to an aqueous solution containing 
10  µM BSA (when all-trans retinol was added) or 5 µM BSA (when all-trans retinaldehyde 
was added) followed by sonication for 10 min. The final concentration of ethanol did not 
exceed 1% v/v. This procedure guarantees a more soluble and stable retinoid substrate 
solution [28]. One volume of 2 M hydroxylamine pH 6.7 and one volume of 100% methanol 
were added to quench the reaction and to stabilize the retinoids. Retinoid extraction from 500 
µl of the homogenates was optimized by adding acetone (1 volume) as a phase mixing agent 
followed by three times extraction with petrol ether (0.6 volumes). The organic solvent was 
evaporated under a stream of nitrogen and the retinoid pellet was dissolved in 100 µl of 
HPLC mobile phase (99.5 hexane: 0.5 ethanol), and injected into the HPLC. The relative 
amounts of retinaldehyde and retinol are expressed as percentages (the amount of a retinoid 
specie divided by the total amount of all retinoids present).  
Real time PCR- Total RNA was extracted from C2C12 cells and treated with 
Deoxyribonuclease I as previously described [29]. After reverse transcription using 1000 ng 
of RNA, cDNA was amplified by quantitative real-time PCR using SYBR Green technology 
as previously described [29] and the following primers: RyR1  (forward 5′-
GCACACAGTCGTATGTACCTG-3′ and reverse 5′-CCTCCCCTGTTGCGTCTTC-3′), 
SRP-35 (forward 5`-CCCTGGAGCTTGACAAAAAGA`-3′ and reverse 5′-
GTTCACTAACACAATCTGGCCT-3′) Cav1.1 (forward 5`- 
TCAGCATCGTGGAATGGAAAC-3′ and reverse 5′-GTTCAGAGTGTTGTTGTCATCCT-
3′). Gene expression was normalized using self-TATA box binding protein (TBP) as 
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reference and the following primers: forward, 5'- GCCATAAGGCATCATTGGAC-3' and 
reverse, 5'-AACAACAGCCTGCCACCTTA-3'. 
Software and statistical analysis- Blast alignments were performed on the NCBI web site 
using BLAST 2.2.8. Multiple sequence alignments were performed using the Clustal W 
algorithm available from the Swiss node of the European Molecular Biology Network. 
Statistical analysis was performed using the Student’s t test for two populations. Values were 
considered significant when P<0.05.  
 
RESULTS 
Primary structure of SRP-35- The skeletal muscle sarcoplasmic reticulum junctional face 
membrane is enriched in proteins playing a major role in Ca2+ homeostasis. One of the aims 
of the research of our and other laboratories is to identify all the protein constituents of this 
membrane fraction [10,11,30]. Results obtained by electronspray mass spectrometry analysis 
revealed the presence of a novel polypeptide with an approximate molecular mass of 35 kDa 
in the sarcoplasmic reticulum. Based on the amino acid sequence obtained from two peptides 
of the 35 kDa rabbit skeletal muscle protein (Fig.1 light grey boxes), primers were designed 
and used to amplify by RT-PCR (from mouse skeletal muscle mRNA) a cDNA sequence of 
approximately 960 nucleotides, whose primary sequence matched that of a hypothetical 
mouse protein present in the NCBI database (see Fig. 1). The predicted primary sequence of 
SRP-35 encompasses (i) the peptide sequences obtained from the rabbit skeletal muscle 
protein from which primers were designed (light grey boxes); (ii) an amino terminal 
hydrophobic sequence (dark grey box) which may be a signal sequence or a trans-membrane 
domain; (iii) an NAD(P)(H)-binding and catalytic site (underlined sequence); the bold letters 
indicate perfectly conserved residues within the NAD(P)(H)-binding and catalytic sites. Blast 
search analysis of the human genome revealed that the human homologue of the rabbit 
protein maps to human chromosome 17p13.1 (access number NM_00110557) and 
specifically to the DRS7C_human locus (dehydrogenase/reductase SDR family member 7C 
or SDR32C2); polymorphisms/mutations have so far not been associated with any human 
genetic disorder. Figure 1 also shows that SRP-35 is conserved among mammals (87-95% 
identity with the mouse sequence); however not all vertebrates express the 7C member of the 
SDR family of dehydrogenase/reductases and in fact BLAST analysis revealed that the gene 
encoding SDR7C is less conserved but present in the genomes of Xenopus (73% identity), 
Drosophila (38% identity) and Zebrafish (58% identity). 
Tissue distribution, subcellular localization and membrane topology of SRP-35- In order to 
gain information concerning its physiological function, we analysed the tissue distribution of 
SRP-35 by western blot using two anti-SRP35 polyclonal antibodies (with similar results), 
one raised against the GST-SRP-35 fusion protein and the other, a commercially available 
one, raised against the putative DHRS7C gene product. Figure 2A shows that an 
immunoreactive band of approximately 35 kDa is present in the total homogenate of different 
mouse tissues, including adipose tissue, liver and skeletal muscle. Interestingly, in liver SRP-
35 is not present in the microsomal fraction but remains in the 100,000 g supernatant (figure 
2B), while in skeletal muscle it is highly enriched in the total SR fraction (figure 2C) and 
undetectable in the post microsomal supernatant (result not shown). In all other tissues tested 
the 35 kDa immunoreactive protein is undetectable in the microsomal fraction. These results 
indicate that in muscle, SRP-35 may interact with macromolecules that are exclusively 
present in skeletal muscle. Because we were interested in the functional role of SRP-35 in 
skeletal muscle, all subsequent experiments were performed on this tissue.  
The subcellular distribution of SRP-35 was analysed: (i) in isolated fractions of the 
sarco(endo)plasmic reticulum, (ii) by monitoring the expression of GFP-tagged SRP-35 in 
C2C12 myotubes and (iii) by confocal microscopy on mature mouse skeletal muscle 
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longitudinal sections. Figure 2D shows that SRP-35 is enriched in the skeletal muscle fraction 
corresponding to the longitudinal SR. Quantitative immunoblot analysis revealed that the 
immunopositive band corresponding to SRP-35 is enriched 6 fold (5.97± 0.2, mean± SEM;n= 
6) in longitudinal sarcoplasmic reticulum compared to total muscle homogenate 
(Supplementary Fig. 1). These results are compatible with the distribution of fluorescence in 
C2C12 myotubes transfected with GFP-tagged SRP-35 (figure 2F). As shown, transfection of 
C2C12 cells with pEGFP results in an even cytoplasmic distribution of GFP-fluorescence, 
whereas when cells expressed the SRP-35-GFP fusion protein, the resulting punctuated 
fluorescence is compatible with the localization of SRP-35 in a membrane bound organelles. 
High-resolution confocal analysis on longitudinal sections of mouse skeletal muscle, shows a 
cross-striated distribution of endogenous SRP-35 with a centre to centre distance between the 
bands of approximately 1.5 µm. This fluorescent pattern partially overlaps with that of the 
SERCA pump (see Supplementary Figure 2), indicating a common subcellular distribution.  
A similar expression pattern was observed after in vivo transfection of FDB fibres with the 
SRP-35-EGFP construct (not shown). Interestingly and as shown in figure 2H slow twitch 
fibres contain significantly less SRP-35 than fast twitch fibres (the mean ±SEM, n=6 
percentage intensity of the immunopositive band in western blots from soleus was 69.7±5.6% 
of that from EDL P<0.0001). 
Based on its deduced primary sequence, the amino-terminal of this protein 
encompasses a hydrophobic peptide of 24 residues, which could be a signal sequence or may 
form a trans-membrane alpha-helical segment. To establish whether in skeletal muscle SRP-
35 is an integral membrane protein we (i) extracted SR vesicles with KCl/Na2CO3 and (ii) 
performed trypsin digestion followed by western blot analysis. Treatment of mouse total SR 
membrane fraction with 0.6M KCl, a procedure used to separate loosely bound proteins from 
the membrane of microsomal vesicles, did not dissociate SRP-35 from the SR vesicles 
(Fig.3A left panel). The failure to extract SRP-35 with high-ionic strength wash might be due 
to the localization of SRP-35 in the lumen of the SR vesicles similarly to calsequestrin (Fig. 
3A right panel) or it might result from its integral association to the SR membrane. To 
discriminate between these possibilities we performed an alkaline extraction of the SR 
fraction with 100 mM Na2CO3. As expected, calsequestrin (fig. 3B right panel), an intra-
lumenal SR protein, was found in the Na2CO3 solubilized fraction. In contrast, SRP-35 was 
still associated with the insoluble membrane fraction (fig. 3B left panel), as was calnexin, a 
90 kDa integral membrane protein of the endoplasmic reticulum (fig. 3B central panel). We 
further tested under what conditions SRP-35 could be solubilized, by treating SR vesicles 
with different detergents (CHAPS, DHPC and DDM) under high ionic conditions. As shown, 
extraction with 1% CHAPS was not efficient, whereas the treatment of SR vesicles with 1% 
DHPC or DDM in the presence of 1M NaCl was equally efficient at solubilizing SRP-35 
(figure 3C).  Finally, the topological orientation of SRP-35 was assessed by proteolysis of SR 
vesicles with increasing concentrations of trypsin. Under our experimental conditions, the 
immunoreactivity of SRP-35 decreased with increasing trypsing concentration even at very 
low trypsin concentrations (30 and 150 ng) while at these concentrations the 
immunoreactivity of calregulin, which is a luminal SR protein and thus not exposed to 
trypsin, was unaffected (figure 3 panels D). These results indicate that the majority of the 
SRP-35 polypeptide, including its epitope(s), protrudes from the SR vesicles and is exposed 
towards the myoplasm and only a small portion is bound to the SR membrane.  
SRP-35 binds the dinucleotide NAD(H) and has catalytic activity- In silico comparison 
analysis of the deduced amino-acid sequence of SRP-35 revealed that it shares homology 
with proteins belonging to the short-chain dehydrogenases/reductases family. In order to 
determine whether it indeed binds dinucleotides, the affinity column HiTrap Blue Sepharose 
was used; the ligand Cibacron Blue F3G-A shows structural similarities to NAD(H) enabling 
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proteins strongly binding to this cofactor to attach to the resin [26]. Solubilized SR proteins 
were incubated with HiTrap Blue Sepahrose, the resin was extensively washed and bound 
proteins were eluted with 1 M NaCl plus NADH. The fraction(s) enriched in SRP-35 were 
identified by immunostaining with anti-SRP-35 antibodies. Figure 4 shows a representative 
result; the left panels of figure 4A and B are Ponceau-Red stained membranes while the right 
panels are the same blots stained (A) with anti-SRP-35 antibodies and (B) with anti-
calsequestrin antibodies as control. An immunoreactive band corresponding to SRP-35 is 
present in the total SR (lane 1), in the solubilized SR fraction (lane 3) and in the NADH 
eluted fraction (lane 6). Not all SRP-35 was eluted with NADH as demonstrated by the 
presence of an immunoreactive band of 35 kDa in an aliquot of the Cibacron Blue F3G-A 
resin (lane 7). On the other hand, when the same experiment was performed by following the 
distribution of calsequestrin, a major SR protein which should not bind to Cibacron Blue 
F3G-A, its immunoreactivity is present in the total SR but not in the NADH eluate nor bound 
to the resin.  
Since SRP-35 shares homology with the catalytic domains of classical SDR family 
members that convert, among others, retinol substrates to retinaldehyde derivatives, 
concomitantly reducing NAD, we set up an assay to validate the enzymatic activity of SRP-
35 by verifying if its over-expression affects the amount of all-trans retinol (ROL) converted 
to all-trans retinaldehyde (RAL). As an experimental setup we chose an ‘in situ’ whole cell 
assay in which transiently transfected cells (HEK293 cells or C2C12 myotubes) were 
incubated with all-trans retinol or all-trans retinaldehyde and the amount of product formed 
was compared to that obtained in cells transiently transfected with the empty pEYFP plasmid. 
Panels C and D of figure 4 show original HPLC chromatograms obtained from lipid extracts 
of YFP and SRP-35- YFP transfected HEK293 cells, panels E and F show the cumulative 
results obtained by pooling data from three independent transfection experiments and 
normalized for the relative amount of all-trans retinaldehyde-oxim (peaks 2 and 5) and 
retinol (peak N° 4) divided by the total amount of peaks 1 through 5, defined as 100% (the 
total amount of all intracellular retinoids present in the lipid extracts). As shown, HEK293 
cells over-expressing SRP-35 generate a significantly larger proportion of all-trans 
retinaldehyde (RAL; sum of peaks 2 and 5) compared to YFP transfected controls (fig. 4E). 
Interestingly, the reaction appears to preferentially proceed in the forward oxidative reaction 
since no change in the relative amount of all-trans retinol (ROL) was obtained in SRP-35 
over-expressing cells (fig. 4F). Similar results were obtained in C2C12 transfected myotubes 
(results not shown). In addition, 13-cis retinol was sometimes detected in the SRP-35- 
transfected HEK293 cells (peak 3), but may be an artefactual change of all-trans-retinol due 
to extraction procedure. We also verified if SRP-35 over-expression affects the overall redox 
status of cells by performing Oxy-Blot analysis on total extracts of GFP and SRP-35-GFP 
transfected HEK293 cells; as shown in Supplementary figure 3 cells transfected with the 
SRP-35 fusion protein exhibited a significant increase in the quantity of oxidatively modified 
proteins, confirming that SRP-35 is indeed involved in redox reactions. 
Effect of SRP-35 over-expression on excitation-contraction coupling- SRP-35 is located 
within a subcellular membrane devoted to the regulation of the [Ca2+], thus we investigated if 
its over-expression affects Ca2+ homeostasis. C2C12 mytotubes were transfected with the 
SRP-35-EYFP or with the empty pEYFP vector, loaded with fura-2 and individually 
stimulated with different concentrations of either KCl (mimicking depolarization) or 4-
chloro-m-cresol (inducing direct activation of the RyR1). As shown in figure 5 over-
expression of SRP-35 affected neither the resting [Ca2+] (fig. C) nor the EC50 for KCl (26.2 
±0.8 and 27.6± 1.8 mM for YFP and SRP-35-YFP over-expressing cells, respectively; fig. 
5A) and 4-chloro-m-cresol (340.6±32.6 and 306.7±16.9 µM, for YFP and SRP-35-YFP over-
expressing cells, respectively; fig. 5B) induced Ca2+ release; however, it significantly 
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decreased by approximately 40% the peak Ca2+ release induced by maximal stimulatory 
concentrations of KCl (fig.5D; P<0.05) and 4-chloro-m-cresol (fig. 5E; P<0.008). This 
decrease in peak Ca2+ release was not due to depletion of intracellular stores since the peak 
Ca2+ transients elicited by a treatment aimed depleting intracellular stores (5 µM ionomycine 
+ 1 µM thapsigargin in 0.5 mM EGTA) were not significantly different (∆ fluorescence ratios 
were 0.251±0.041 and 0.205±0.048; P=0.479 in YFP and SRP-35-YFP expressing cells). 
Interestingly, addition of retinoic acid to C2C12 during myotube differentiation mimicked the 
effect of SRP-35 over-expression by causing a significant decrease in the peak Ca2+ induced 
by KCl (fig. 5D; P<0.01) and 4-chloro-m-cresol (fig. 5E; P<0.008). The reduced Ca2+ release 
could be due to allosteric regulation by products deriving from the enzymatic activity of SRP-
35 such as NADH and/or to alterations of the level of expression of the proteins involved in 
excitation-contraction coupling. The latter event may result from the effect of retinoic acid 
generated from the retinaldehyde produced by SRP-35. In order to investigate this, we 
performed Real Time PCR on mRNA extracted from C2C12 myotubes treated in culture with 
5 µM retinoic acid. We chose this approach to avoid the variability linked to the efficiency of 
transient transfections of C2C12 cells. Figure 5F shows that retinoic acid treatment of C2C12 
myotubes induces a 2.5 fold induction in the level of expression of SRP-35; no affect was 
observed on the expression level of the alfa 1.1 subunit of the voltage sensing DHPR (fig.5G) 
but, interestingly, it caused a significant reduction (fig.5H; P<0.025) in the expression level 
of the mRNA encoding RyR1. This decrease in the RyR1 transcript was paralleled by a 
decrease in the content of the RyR1 protein as confirmed by western blot analysis 
(Supplementary figure 4). The extent of decrease of the mRNA level is similar to the extent 
of decrease of Ca2+ release observed after pharmacological activation of the RyR1 and most 
likely results from changes in the protein level of the RyR1 induced by retinoic acid 
production after 6 days of SRP-35 over-expression.   
 
DISCUSSION 
 The skeletal muscle sarcoplasmic reticulum is an organelle specialized in regulating 
calcium homeostasis and identifying all its protein components constitutes a major step 
towards the elucidation of the regulation of calcium under normal and pathological 
conditions. In the present report we identified SRP-35 and show that this novel component of 
the skeletal muscle SR belongs to the short-chain dehydrogenase/reductase protein family, an 
enzyme whose activity may link calcium homeostasis to activation of metabolism. 
 The enzyme superfamily of short chain dehydrogenases consits of more than 46’000 
family members which are ubiquitously expressed and whose transcripts have been found in 
virtually all genomes investigated [12, 31,32]. In the presence of specific co-factors they 
dehydrogenate numerous substrates including sterols, 3-hydroxysterols, alcohols, retinols, 
sugars, aromatic compounds and xenobiotics [33] thus playing critical roles in lipid, amino 
acid and carbohydrate metabolism; they also regulate many physiological processes by 
sensing the redox status in metabolism and transcription [13]. Although SDR share little 
genetic similarity (15-30%) [32], some sequence motives of their tertiary structures resemble 
each other [13] and, importantly, their co-factor binding domain is highly conserved. In 
humans and mouse at least 70 distinct SDR have been identified: they have a highly variable 
C-terminal substrate binding domain, but all contain a Rossmann-fold scaffold and bind 
NAD(P) dinucleotides [13, 31]. SRP-35 contains a Tyr residue with adjacent Lys and Ser 
residues in its active site but is slightly larger than “classical” SDR, being 311 rather than the 
classical 250 residues long; thus it should be classified as an “extended” member of the SDR 
superfamily [13]. Among the many functions catalyzed by SDR family members, some are 
involved in retinol/retinladehyde metabolism. Indeed, retinols (such as vitamin A) that are 
taken in with the diet, are transported at high concentrations via the serum, bound to retinol-
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binding protein and can be taken up by any cell for storage or potential conversion to retinoic 
acid.  Once inside the cell they are converted to retinal via a reversible reaction catalysed by 
SDR (or Alcohol dehydrogenases), first to retinaldehyde with the concomitant generation of 
NADH and subsequently to retinoic acid by cytosolic aldehyde dehydrogenases (Aldh1a1 to 
Aldh1a3) [34,35].  
 The results of the present investigation support a role for SRP-35 in the conversion of 
retinol to retinaldehyde and thus to its involvement in the retinoic acid signalling pathway in 
skeletal muscle. Skeletal muscles express RAR and high levels of RXRγ [15, 36, 37], 
receptors that can activate the muscle specific transcription factors myogenin and myoD [38, 
39] and treatment of muscle cells in culture with retinoic acid has been shown to stimulate 
myotube differentiation [39, 40].  
 An intriguing aspect of SRP-35 is its particular tissue and subcellular distribution; in 
fact western blot analysis of different tissues revealed that it is abundantly expressed in liver 
and kidney where it is absent from the microsomal fraction but present in the post 
microsomal supernatant. Indeed SDRs have been found in the cytosol, in organelles such as 
the endoplasmic reticulum and mitochondria as well as in low density peroxisomes [41, 42], 
the latter being too light to be pelleted by a 1 hour centrifugation at 100’000 g. In order to 
investigate whether in liver and kidney SRP-35 is present in “light“ membrane fractions, a 
more detailed analysis of rough and smooth ER, peroxisomes and lysosomes should be 
carried out. Nevertheless, in skeletal muscle SRP-35 is present in the SR and based upon our 
subcellular fractionation experiments, it is enriched in the longitudinal SR, a fraction also 
enriched in proteins such as the SERCA pump and sarcalumenin [for a recent review see ref. 
11]. Such a distribution is compatible with the high resolution confocal immunofluorescence 
experiments of endogenous SRP-35 which revealed the presence of cross striated bands, a 
pattern which is similar and partially overlaps with the distribution of SERCA. We cannot 
exclude that in skeletal muscle targeting of SRP-35 to the longitudinal sarcoplasmic 
reticulum is mediated by its interaction with other proteins. Co-immunoprecipitation 
experiments did not reveal any interaction with either SERCA1 or SERCA2 (not shown) and 
binding to other SR proteins may be of low affinity and thus easily disrupted by the high salt 
concentration and detergents required to solubilize SRP-35. Interestingly, quantitative 
analysis of the content of SRP-35 in slow and fast twitch muscles indicates that this protein is 
enriched in fast twitch muscles; though of potential significance this may be due to the fact 
that the relative volume of the SR is almost double in EDL compared to soleus muscles [43-
45].  
 The biochemical characterization of this novel muscle SDR strongly support that it is 
a membrane bound protein with its catalytic site facing the cytoplasm; in fact (i) it could not 
be extracted by treating vesicles with high salt or bicarbonate, methods which have been 
successfully used to extract loosely bound or soluble proteins from the ER/SR [23, 24, 46] 
and (ii) mild detergents such as CHAPS were not efficient at solubilising SRP-35. (iii) 
Trypsin digestion revealed that most of the protein faces the myoplasm; thus both its product 
(retinaldehyde) and NAD(P)H would be released into the myoplasm. The generation of 
NADH in the myoplasm may have functional signalling relevance; in fact lactate 
dehydrogenase requires NADH as reducing power to generate lactate from pyruvate and 
though NADH is available in the mitochondria where it is used to generate ATP, there are no 
transporters for NADH and therefore the reduced co-factor must be regenerated in the 
cellular compartments where it is consumed [47]. It should also be mentioned that cytosolic 
NADH has been shown to regulate the activity of the RyR, especially in the heart [48, 49].  
Although we are aware that SRP-35 is a low abundant SR protein and we do not exactly 
know the stoichiometric ratio between SRP-35 and RyR1, we speculate the NADH generated 
by SRP-35 in a microdomain adjacent to SR membranes might allosterically modulate RyR1 
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activity. We can also not exclude the possibility that SRP-35 indirectly modulates Ca2+ 
release by affecting the level of expression of the RyR1 protein. 
 Our results show that over-expression of SRP-35 in C2C12 myotubes results in a 
decrease of RyR1-mediated Ca2+ release, a result that could be mimicked by the addition of 
retinoic acid to the culture medium during differentiation. Indeed both the Ca2+ release 
induced by KCl (mimicking depolarization) as well as that induced by direct activation of 
RyR1 were reduced by approximately 40% with no significant change in the EC50 for either 
agonist. Such a result is reminiscent of the effect of mutations in the RYR1 gene linked to 
some forms of central core disease and multiminicore disease; in fact mytubes from such 
patients have reduced pharmacologically evoked Ca2+release, and, depending on the mutation 
increased or normal resting [Ca2+] and/or reduced expression of RyR1 in muscle [25, 50-52].  
In the case of SRP-35, the decreased Ca2+ release was not accompanied by a change in the 
resting [Ca2+] nor in the Ca2+ present in intracellular stores suggesting that the effect was not 
due to a modification of Ca2+ fluxes across surface membranes [53] but likely due to reduced 
expression of components of the Ca2+ release units. Real time PCR on RA treated cells shows 
that the level of expression of the Cav1.1 was not affected but that of the RyR1 was reduced 
by approximately 50%. A result confirmed by immunoblotting. A similar effect of retinoic 
acid treatment on the expression of inositol- 1,4,5-trisphoshate receptors has been reported 
[54, 55] and is thought to be due to a decrease in the promoter activity in response to retinoic 
acid.  
 What is the function of SRP-35 in vivo and what is the physiological activator of this 
short chain dehydrogenase? Skeletal muscle constitutes approximately 40% of the total body 
mass, accounts for more than 30% of energy expenditure and is the major tissue involved in 
insulin-dependent glucose uptake. Metabolism is largely regulated by nuclear hormone 
receptors that function as regulators of transcription and it has been demonstrated that in mice 
retinoic acid treatment favours mobilization of body fat, increases fatty acid oxidation and 
decreases body weight [20, 56]. Though at the moment it is difficult to envisage what 
activates the enzymatic activity of SRP-35, its strategic subcellular localization in a 
compartment dedicated to Ca2+ homeostasis and the fact that during the conversion of retinol 
to retinaldehyde it would concomitantly generate NADH, indicates that it may be an 
important molecule linking Ca2+ mobilization and thus muscle contraction to the activation of 
metabolic functions. SRP-35 is a dehydrogenase and could reduce the NAD+ generated by 
lactate dehydrogenase during sustained muscle activity. In fact the NAD+ which is generated 
during glycolysis remains in the cytoplasm since the inner mitochondrial membrane lacks a 
specific transport system [47]. Interestingly many enzymes involved in the glycolytic 
pathway adhere to the sarcoplasmic reticulum membranes [21]. The reduction of NAD+ by 
SRP-35 is coupled to the conversion of all-trans- retinaldehyde to retinoic acid, an important 
activator of GLUT4 gene transcription [57] and regulator of RyR1 expression (Fig 5). 
Additionally a secondary effect of SRP-35 could be mediated by NADH which has been 
shown to regulate ryanodine receptor activity [49].  The development of an experimental 
model over-expressing SRP-35 in its skeletal muscle will allow us to investigate in greater 
detail many aspects of this novel short chain dehydrogenase
ranging from metabolism to activation of transcription of specific genes.
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FOOTNOTES 
 
Abbreviations: CHAPS, 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate; DDM, n-dodecyl-beta-D-maltoside; DHPC, 1,2-diheptanoyl-sn-
Glycero-3-phosphocholine; DHPR, dihydropyridine receptor; LSR, longitudinal 
sarcoplasmic reticulum; RA, retinoic acid; RAL, all-trans retinaldehyde; RAR, retinoic 
acid receptor; ROL, all-trans retinol; RXR, retinoid X receptor; RyR, ryanodine 
receptor; SDR, short chain dehydrogenase; SERCA, sarco(endo)plasmic reticulum 
CaATPase; SR, sarcoplasmic reticulum.
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FIGURE LEGENDS 
 
Figure 1. Predicted primary sequence of mouse SRP-35 and comparison with that of 
other vertebrates. Dark grey box indicates hydrophobic residues encoding the putative 
transmembrane domain. The two light grey boxes indicate the peptide sequences obtained 
from rabbit skeletal muscle SRP-35 from which primers were designed. Underlined residues 
indicate catalytic consensus sequence and the bold letters indicate perfectly conserved 
residues within the NAD(P)(H)-binding site. 
 
 
Figure 2. Tissue and subcellular distribution of SRP-35. A. Total homogenates (30 
µg/lane) from the indicated mouse tissues were separated on a 12.5% SDS-PAG, blotted onto 
nitrocellulose and probed with anti-SRP-35 Ab. B. Total liver homogenate, the microsomal 
fraction (100,000 g pellet) or post microsomal supernatant (100,000 g sup) (30 µg/lane) were 
loaded on a 12.5% SDS-PAG, blotted onto nitrocellulose and probed anti-SRP-35 Ab. C. 
Total SR from mouse skeletal muscle or the microsomal fraction from the indicated tissues 
(50 µg/lane) were separated on a 10% SDS-PAG, blotted onto nitrocellulose and probed with 
anti-SRP-35 antibody. D. Total mouse SR was fractionated into light (PM), longitudinal 
sarcoplasmice reticulum (LSR) and terminal cisternae (TC) (30 µg/lane); proteins were 
separated on a 10% SDS PAG, blotted onto nitrocellulose and probed with anti-SRP-35 Abs. 
E. C2C12 myotubes transfected with the plasmid encoding pEGFP were visualized by 
brightfield (left) or under fluorescent light with a 20x water-immersion FLUAR objective 
(0.75 numerical aperture). F. C2C12 myotubes transfected with the plasmid encoding SRP-35-
EGFP were visualized by brightfield (left) or under fluorescent light. Note that in these cells 
fluorescence is punctuated and excluded from the nuclei (bar indicates 50 µm). G. 
Longitudinal sections of mouse skeletal muscle were stained with anti-SRP-35 followed by 
anti-rabbit conjugated Alexa-Fluor 488. Muscle tissue was visualized with a Leica DM1400 
Confocal microscope equipped with a HCX APO 100x oil immersion TIRF objective (1.47 
N.A.). Images (1024x1024) were acquired at 400 Hz through a 1 µm pinhole; note the striated 
distribution of SRP-35 compatible with a membrane localization. Bar indicates 10 µm. H. 
Total homogenates (20 and 40 µg) of fast (EDL) and slow (soleus) muscles were loaded on a 
10% SDS PAG, the proteins were blotted onto nitrocellulose and probed with anti-SRP-35 
Abs as described above. Immunoreactivity with albumin was used as a control to show that 
similar amounts of proteins were loaded. 
 
Figure 3 SRP-35 is tightly associated with sarcoplasmic reticulum membranes and the 
majority of the protein faces the myoplasm. Total mouse SR microsomes were incubated 
for 30 min on ice with either (A) KCl or (B) Na2CO3 and centrifuged at 150,000 g for 45 min. 
Proteins present in the supernatant and in the pellet were separated on a 12.5 % SDS-PAGE 
and stained with anti-SRP-35 antibodies or Stains-All (to visualize calsequestrin which stains 
metachromatically blue). (C) Total mouse skeletal muscle sarcoplasmic reticulum  (1 mg/ml) 
was treated with the indicated detergent (1%) in presence of 1M NaCl for 30 min at 4°C. 
After centrifugation at 135,000 g, pellets and supernatant were collected and proteins (30 
µg/lane) were separated by a 12.5 % SDS-PAGE, blotted onto nitrocellulose and stained with 
SRP-35 Abs. Total sarcoplasmic reticulum from mouse skeletal muscles (50 µg protein) were 
treated with increasing concentrations of trypsin, for 2 min at RT.  After treatment, the 
reaction was blocked and proteins were loaded onto a 12.5% SDS-PAGE, blotted onto 
nitrocellulose and stained with antibodies against SRP-35 (left) and calregulin (as a control 
for vesicle integrity). NT: no treatment; 
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Figure 4 SRP-35 is a dinucleotide binding protein and its over-expression leads to an 
increased production of all-trans retinaldehyde. SRP-35 binds Cibacron Blue F3G-A a 
ligand. A: 1 mg/ml total SR vescicles were solubilized in a solution containing 1% DDM, 1M 
NaCl and subsequently incubated with Cibacron Blue F3G-A resin as described in the 
Methods section. Proteins present in the total SR (30 µg, lanes 1), pellet after solubilization 
with DDM/NaCl (30 µl lane 2), total SR proteins solubilized with DDM/NaCl (30 µl, lane 3), 
void (30 µl, lane 4), last wash (30 µl, lane 5), eluted with NADH (30 µl, lanes 6) and attached 
to the resin (30 µl, lanes 7). Left panel, Ponceau Red stained blot; right panel, blot stained 
with anti-SRP-35 Abs. B as A, except that blot was stained with anti-calsequestin antibodies. 
Note that calsequestrin does not bind to Cibacron Blue F3G-A. C and D: Chromograms (325 
nm) of the homogenates of pEYFPC1 and pEYFPC1-SRP-35 transfected HEK293 cells. All-
trans retinylester (1), all-trans retinaldehyde-oxim (syn: 2; anti: 5) (RAL), 13-cis retinol (3) 
and all-trans retinol (4) (ROL). The peaks are identified by authentic standards. E and F: Bar 
histograms comparing the percentage of Retinaldehyde and Retinol present in pEYFPC1 and 
pEYFPC1-SRP-35 transfected cells. Results are the mean (± SEM) of the experiments. The 
percentage of RAL in cells over-expressing SRP-35 was significantly higher than in YFP-
transfected cells, P<0.019.  
 
Figure 5 Effect of SRP-35 on calcium fluxes in C2C12 myotubes. A and B: KCl- and 4-
chloro-m-cresol dose response curves in C2C12 transfected with pEYFPC1 (full line) or 
pEYFPC1-SRP-35 (dashed line). Data points represent the mean peak fluorescence increase 
of 6-11 cells. Curves were fit using a Boltzmann equation; there were no significant 
differences in the EC50 for KCl or 4-chloro-m-cresol. C: SRP-35 over-expression does not 
affect the resting [Ca2+] of C2C12 cells. D and E: Peak fura-2 ∆ fluorescence (mean ± SEM of 
the indicated number of cells) in C2C12 transfected with pEYFPC1 (empty bars), pEYFPC1-
SRP-35 (dark grey bars), untreated (empty bars) and treated with retinoic acid (5 µM) for 4 
days. * P<0.005; ** P<0.01; *** P<0.008. F, G and H: real time RT-PCR on control or RA 
treated C2C12 cells.  RA does not affect the relative expression level of CaV1.1, but it 
significantly increases the relative expression level of SRP-35 while decreasing that of RyR1. 
Results are expressed as mean± SEM of the indicated number of experiments. *** P< 0.001. 
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